Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Adherence news

Show

From To
South Africa forces recall of Cipla’s Duovir in response to WHO concerns

The South African Medicines Control Council (MCC) has told doctors in South Africa that the use of Cipla’s Duovir formulation of zidovudine (AZT) and lamivudine

Published
12 August 2004
By
Keith Alcorn
Study looks at risky sex amongst 3,700 HIV-positive Americans

Most of the sex engaged in by a sample of over 3,700 HIV-positive Americans over a three month period did not carry a risk of

Published
04 August 2004
By
Michael Carter
US approval for once daily abacavir/3TC and tenofovir/FTC pills

The US Food and Drug Administration announced Monday that it has approved two once daily combination tablets manufactured by Glaxo SmithKline and Gilead. The Glaxo SmithKline

Published
03 August 2004
By
Keith Alcorn
Is paying for treatment affecting adherence in Africa?

Making patients in impoverished countries contribute towards the cost of their antiretroviral treatment is one of the major causes of non-adherence to treatment according to

Published
27 July 2004
By
Keith Alcorn
HAART reduces HIV transmission by 53% in Taiwan

The provision of free HAART decreased HIV transmission by 53% in Taiwan, according to an article published in the Septmber 1st edition of The Journal

Published
26 July 2004
By
Michael Carter
Fewer pills means better adherence, says Spanish study

Switching from a protease inhibitor-based HAART regimen to an efavirenz-based regimen led to a significant improvement in the level of adherence in a Spanish cohort

Published
23 July 2004
By
Michael Carter
Once-daily regimens improve adherence and treatment satisfaction

Once-daily HAART regimens are just as potent as twice-daily regimens and significantly improve patient adherence and satisfaction, according to a Spanish study presented as a

Published
23 July 2004
By
Michael Carter
Pilot study finds weekend breaks from HAART may be possible on NNRTIs

An intriguing study presented on the second day of the Fifteenth International AIDS Conference examining the feasibility of intermittent therapy taken five days a week,

Published
14 July 2004
By
Edwin J. Bernard
Once-daily treatment not a golden bullet for improved adherence, multiple factors important

Assuming that a regimen would be easier to adhere to just because it is once-daily could mean that other important factors affecting adherence are neglected,

Published
23 June 2004
By
Michael Carter
Risk factors for non improvement in HAART adherence identified in MACS

A US study has found that there are specific factors associated with imperfect adherence to HAART, and with a failure to improve adherence. The study

Published
10 March 2004
By
Michael Carter

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.